Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
10/2003
10/02/2003CA2479880A1 Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
10/02/2003CA2479722A1 Combination of an aldosterone receptor antagonist and a fibric acid derivative
10/02/2003CA2479671A1 Combination of an aldosterone receptor antagonist and nicotinic acid for a nicotinic acid derivative
10/02/2003CA2479279A1 Fused bicyclic pyridine derivative as tachykinin receptor antagonist
10/02/2003CA2479277A1 Fused bicyclic pyrimidine derivatives
10/02/2003CA2479259A1 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
10/02/2003CA2479256A1 Phosphate prodrugs of fluorooxindoles
10/02/2003CA2479254A1 Preventive or therapeutic agent for renal disease
10/02/2003CA2479150A1 Heteroaromatic urea derivatives as vr-1 receptor modulators for treating pain
10/02/2003CA2478801A1 Method for administration of growth hormone via pulmonary delivery
10/02/2003CA2478327A1 Hgh (human growth hormone) formulations for pulmonary administration
10/02/2003CA2477651A1 Kinase inhibitors
10/01/2003EP1348707A1 Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy
10/01/2003EP1348706A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
10/01/2003EP1348434A1 Use of pyridyl amides as inhibitors of angiogenesis
10/01/2003EP1347990A2 Peptide mit inhibierender aktivität zur produktion von stickstoffmonoxid
10/01/2003EP1347981A1 Condensed purine derivatives as a 1? adenosine receptor antagonists
10/01/2003EP1347980A1 Compounds specific to adenosine-a1,-a2a, and- a3-receptor and uses thereof
10/01/2003EP1347966A1 Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
10/01/2003EP1347780A1 Compositions of n-(methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides
10/01/2003EP1347762A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
10/01/2003EP1347761A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
10/01/2003EP1347760A2 Nmda receptor agonist pharmaceutical compositions
10/01/2003EP1347753A1 Topical composition and method for treating urinary stress incontinence
10/01/2003EP1347751A2 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists
10/01/2003EP1204655B1 A crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy] phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
10/01/2003EP1200447B1 Oxazinocarbazoles for the treatment of cns diseases
10/01/2003EP0811008B1 Bicyclic benzazepine derivatives as vasopressin antagonists
10/01/2003CN1446229A Somatostatin analogues
10/01/2003CN1446227A Novel fibroblast growth factor (FRF23) and method for use
10/01/2003CN1446218A Benzimidazole derivatives, preparation method and therapeutic use thereof
10/01/2003CN1446212A Quinoline derivatives having VEGF inhibiting activity
10/01/2003CN1446193A Aminoadamantane derivatives as therapeutic agents
10/01/2003CN1445357A Dog meat wine for tonifying the kidney and its preparing technique
10/01/2003CN1444987A Compound preparation of Chinese herbal medicine for treating chronic prostatitis and its preparing method
10/01/2003CN1444982A Compound preparation of Chinese herbal medicine for treating damp-heat from the lower-jiao and its preparing technique
10/01/2003CN1122527C Medicine for curing prostatosis and preparation process
10/01/2003CN1122513C Use of compound in medicine for preparation of inhibiting pathological conditions
09/2003
09/30/2003US6627659 Methods of decreasing the effects of oxidative stress in patients undergoing hemodialysis by intravenously administering N-acetylcysteine or a pharmaceutically acceptable salt thereof to the patient.
09/30/2003US6627656 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
09/30/2003US6627649 (2S)-1-((2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4 -dimethoxybenzenesulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2 -carbonyl)pyrrolidine-2-carboxamide, a selective V1a arginine vasopressin receptor antagonist, in combination with the
09/30/2003US6627644 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists
09/30/2003US6627628 Cardiovascular diseases such as hypertension, angina pectoris, heart failure, thrombosis and atherosclerosis. The compounds of formula (I) are able to modulate the body's own production of cyclic guanosine monophosphate (cGMP) and are suitable for
09/30/2003US6627626 Antiinflammation agents and antiarthritic agents colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.
09/30/2003US6627405 53BP2 complexes
09/30/2003US6627195 Binding agents to CD23
09/30/2003US6627187 Containing an amino acid as a stabilizer; long term storage stability
09/30/2003CA2254750C Inhibition of matrix metalloproteases by 2-(.omega.-aroylalkyl)-4-biaryl-oxobutyric acids
09/25/2003WO2003078632A1 Novel receptor polypeptides and polynucleotides encoding the same
09/25/2003WO2003078428A1 Difurylglycolic acid tropenol esters used as anticholinesterase drugs
09/25/2003WO2003078425A1 Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt
09/25/2003WO2003078422A1 Novel pyridone derivative
09/25/2003WO2003078419A1 N-substituted benzothiophenesulfonamide derivative
09/25/2003WO2003078404A1 Pyrimidine derivatives
09/25/2003WO2003078398A1 NON-PEPTIDE GnRH ANTAGONISTS
09/25/2003WO2003078376A1 Nk1 antagonists
09/25/2003WO2003077949A2 Methods of treating diabetes using pde 11a inhibitors
09/25/2003WO2003077919A1 Fluorinated 4-azasteroid derivatives as androgen receptor modulators
09/25/2003WO2003077914A1 N3 alkylated benzimidazole derivatives as mek inhibitors
09/25/2003WO2003077901A1 Preventing and/or treating cardiovascular disease and/or associated heart failure
09/25/2003WO2003077897A1 Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
09/25/2003WO2003077892A2 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases
09/25/2003WO2003077847A2 Substituted amides
09/25/2003WO2003077840A2 Method of modulating inflammatory response
09/25/2003WO2003077657A1 Choline-silicic acid complex with osmolytes and divalent trace elements
09/25/2003WO2003068171A3 Method and composition for treatment of inflammation and aids-associated neurological disorders
09/25/2003WO2003042411A3 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
09/25/2003WO2003039451A3 Thiazole pyridazinones as adenosine antagonists
09/25/2003WO2003029199A9 Benzene derivatives, process for preparing the same and use thereof
09/25/2003WO2003013530A3 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
09/25/2003WO2002100412A3 Stabilized dispersion of phytosterol in oil
09/25/2003WO2002083112A3 Method for the treatment of polycystic kidney disease
09/25/2003WO2002077263A3 Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
09/25/2003WO2002074733A3 Tryptase-inhibitors
09/25/2003WO2002064634A3 Human monoclonal antibodies to fc alpha receptor (cd89)
09/25/2003WO2002036573B1 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
09/25/2003WO2002030884A3 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
09/25/2003WO2002030882A3 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
09/25/2003WO2002024910A3 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof
09/25/2003US20030182668 Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
09/25/2003US20030181728 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
09/25/2003US20030181658 Exhibit protease activity as a single chain or as an activated two chain form; use of polypeptides to identify compounds that modulate the protease activity thereof and as tumor markers
09/25/2003US20030181587 Thermoplastic resin composition
09/25/2003US20030181519 Substituted phenyl naphthalenes as estrogenic agents
09/25/2003US20030181507 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
09/25/2003US20030181506 Hetercyclic carboxy compounds such as alpha-methyl-2-naphthalene-methyl 2-(4-fluorophenoxy)-5-oxotetrahydrofuran-2-carboxylate used to selectively regulate induction of cytotoxic effecter macrophages
09/25/2003US20030181498 For therapy of disease mediated by interation of Vascular Cell Adhesion Molecule-1 (VCAM-1) and/or fibronectin and integrin receptor and/or alpha 4 beta 1
09/25/2003US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme
09/25/2003US20030181481 Therapeutic drugs for treating central nervous system disorders
09/25/2003US20030181469 Crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
09/25/2003US20030181458 Preferential serotonin receptors antagonists comprising heterocyclic amines used for prophylaxis or prevention of headaches, sleep, sexual or eating disorders and as antidepressants
09/25/2003US20030181446 Novel N-acylated heterocycles
09/25/2003US20030181439 Use of paullone derivatives for making medicines
09/25/2003US20030181422 Cardioprotective phosphonates and malonates
09/25/2003US20030181388 Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire
09/25/2003US20030181379 Novel fibroblast growth factor (FGF23) and methods for use
09/25/2003US20030181371 Compositions and methods of using collajolie
09/25/2003US20030180877 Gene therapy; drug screening
09/25/2003US20030180394 Extracts from sophora species, method for producing the same and their use
09/25/2003US20030180362 Multi-stage oral drug controlled-release system
1 ... 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 ... 562